Jeddah | BETH
January 28, 2026

Saudi Arabia’s Minister of Industry and Mineral Resources, Mr. Bandar bin Ibrahim Al-Khorayef, inaugurated the Advanced Pharmaceuticals Factory (Bpharma) in Jeddah, in the presence of the CEO of the Saudi Authority for Industrial Cities and Technology Zones (MODON), Mr. Majed Al-Argoubi, marking a strategic addition to the Kingdom’s pharmaceutical manufacturing sector and reinforcing efforts to localize drug production and strengthen supply chain resilience.

The facility is considered one of the Kingdom’s strategic national industrial projects, with an initial investment exceeding SAR 450 million in its first phase. Total investment is expected to surpass SAR 650 million upon completion of the second phase, reflecting strong confidence in the long-term growth and sustainability of Saudi Arabia’s pharmaceutical industry.

Spanning approximately 38,000 square meters, the factory has been designed in line with the latest engineering and operational standards. It features fully automated production systems, supported by advanced industrial technologies regarded among the most sophisticated in the Middle East, significantly enhancing efficiency, quality, and safety levels.

Bpharma houses advanced production lines for sterile pharmaceutical products, with an annual capacity of around 250 million units in the first phase, set to increase to over 450 million units in the second phase. Its product portfolio includes intravenous solutions, emergency and intensive care medications, ophthalmic products, respiratory inhalation therapies, cardiovascular drugs, gastrointestinal treatments, and hemostatic products.

The project is expected to generate high-quality employment opportunities, with approximately 250 jobs in the first phase, rising to nearly 600 positions upon full completion. Special emphasis is placed on developing and empowering Saudi national talent through specialized training and qualification programs.

Speaking on the occasion, Mr. Radwan Batterjee, CEO of Bpharma, emphasized the project’s focus on building national capabilities capable of leading advanced pharmaceutical manufacturing. He noted that around 30% of the plant’s output is earmarked for export to Gulf Cooperation Council (GCC) countries, the Levant, and North Africa, strengthening Saudi Arabia’s position as a regional hub for pharmaceutical industries.

The project aligns with the objectives of Saudi Vision 2030, contributing to drug localization, enhancing pharmaceutical security, increasing local content, and supporting sustainable industrial development across the Kingdom.